StuartHIsaacsonMDFAAN

Movement Disorder

Associate Professor of Neurology at the Florida International University Herbert Wertheim College of Medicine in Miami Director and Founder Parkinson's Disease and Movement Disorders Center of Boca Raton

Join to view full profile

Dr. Isaacson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Isaacson's full profile

Already have an account?

Office
Parkinson’s Disease and Movement Disorders Center of Boca Raton
951 Nw 13th St, Bldg 5-E
Boca Raton, FL 33486
Phone+1 561-392-1818

Fax+1 561-392-8989

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Neuromuscular Medicine (Neurology), 1995 - 1996
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1989 - 1992
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1988 - 1989
Northwestern University The Feinberg School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 1997 - 2026
NY State Medical License 1989 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014-2019
Super Doctor SuperDoctors.com

Clinical Trials

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study Start of enrollment: 2013 Feb 01
Completed
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Start of enrollment: 2012 Dec 01
Completed
Phase 4
A Study to Examine APL-130277 in Patients With Parkinson's Disease Start of enrollment: 2014 Aug 31
Completed
Phase 2
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease Start of enrollment: 2017 Apr 30
Completed
Not Applicable
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's Start of enrollment: 2018 Jan 19
Completed
Phase 3
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) Start of enrollment: 2017 Nov 30
Completed
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
Active, not recruiting
Phase 3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
Completed
Phase 3
Open-label Trial in Parkinson's Disease (PD) Start of enrollment: 2021 Feb 24
Enrolling by invitation
Phase 3
Roles: Contact
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Start of enrollment: 2016 Jul 01
Unknown status
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

104 citations
Droxidopa for the Short‐Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)
Robert A. Hauser, Stuart Isaacson, Jerome P. Lisk, L. Arthur Hewitt, Gerry Rowse
Movement Disorders. 2015-04-15
39 citations
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Robert A. Hauser, Rajesh Pahwa, Caroline M. Tanner, Wolfgang H. Oertel, Stuart Isaacson
Journal of Parkinson's Disease. 2017-01-01
103 citations
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Kapil D. Sethi, Stuart Isaacson
Movement Disorders. 2015-05-01

Press Mentions

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's DiseaseApril 4th, 2022
Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy to Treat Action Tremors in Parkinson's DiseaseOctober 22nd, 2020
Daily Use of Cala Trio Device Effectively Eases Hand Tremors, Trial ReportsSeptember 30th, 2019
Join now to see all